Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials-Reference-Cited by-同舟云学术

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials

Published:2017-07-27 Issue:10 Volume:102 Page:1796-1805
ISSN:0390-6078
Container-title:Haematologica
language:en
Short-container-title:Haematologica

Author:

Brown Jennifer R.,Moslehi Javid,O’Brien Susan,Ghia Paolo,Hillmen Peter,Cymbalista Florence,Shanafelt Tait D.,Fraser Graeme,Rule Simon,Kipps Thomas J.,Coutre Steven,Dilhuydy Marie-Sarah,Cramer Paula,Tedeschi Alessandra,Jaeger Ulrich,Dreyling Martin,Byrd John C.,Howes Angela,Todd Michael,Vermeulen Jessica,James Danelle F.,Clow Fong,Styles Lori,Valentino Rudy,Wildgust Mark,Mahler Michelle,Burger Jan A.

Publisher

Ferrata Storti Foundation (Haematologica)

Subject

Hematology

Cited by 207 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pre-existing cardiovascular disease is associated with an increased risk of cardiovascular events during Bruton tyrosine kinase inhibitor therapy;The Oncologist;2024-09-08

2. Severe infections in patients with chronic lymphocytic leukemia included in trials investigating BTK and BCL2 inhibitors;Critical Reviews in Oncology/Hematology;2024-09

3. Personalized dose selection for the first Waldenström macroglobulinemia patient on the PRECISE CURATE.AI trial;npj Digital Medicine;2024-08-27

4. A retrospective observational study of ibrutinib in chronic lymphocytic leukaemia in a real-life setting in France using the national claims database (OSIRIS);Annals of Hematology;2024-07-05

5. Management der kardiovaskulären Medikation während der CLL-Therapie;InFo Hämatologie + Onkologie;2024-07